PROOF was a phase 3, prospective, randomised, open-label, parallel study conducted at 17 centres globally

Patients were 7 to 56 years of age, with haemophilia A or B and a history of high-titre inhibitor (> 5 BU) or refractory to increased dosing of either FVIII or FIX for ≥ 12 months with low-titre inhibitor (≤ 5 BU).

17 patients received FEIBA prophylaxis treatment at a dose of 85 ± 15 U/kg every other day; and 19 patients received FEIBA on-demand treatment at dosages determined by their treating physicians.

"Taken together, this study [PROOF] and that of [Pro-FEIBA] provide basis for optimism that the therapy of patients with inhibitors can be signi´Čücantly improved with prophylaxis leading to significant reduction in bleeding episodes."1

Learn about the PROOF Study Design >>
Learn about the PROOF Study Clinical Results >>

References

  1. 1. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors [published online ahead of print August 1, 2013]. Haemophilia. 2014;20(1):65-72. DOI:10.1111/hae.12246.

The results are in

In the Pro-FEIBA study (n=26), FEIBA prophylaxis showed a significant reduction in the frequency of bleeding events in severe haemophilia A patients with FVIII inhibitors Read more

Publications

Visit Haemophilia to read the PROOF Study and access to more articles related to managing haemophilia patients with inhibitors. Read more

Sustained activity

FEIBA offers a long dosing interval. Read more

Demonstrated efficacy in prophylaxis

Learn how FEIBA prophylaxis can reduce bleed frequency and preserve joints. Read more

Dosing FEIBA

Learn how to dose FEIBA. Read more